DNA damage repair in breast cancer and its therapeutic implications.
暂无分享,去创建一个
E. Rakha | R. Ali | S. Madhusudan | H. Bryant
[1] A. Cox,et al. Altered RECQL5 expression in urothelial bladder carcinoma increases cellular proliferation and makes RECQL5 helicase activity a novel target for chemotherapy , 2016, Oncotarget.
[2] Trey Ideker,et al. A Network of Conserved Synthetic Lethal Interactions for Exploration of Precision Cancer Therapy. , 2016, Molecular cell.
[3] D. Ogilvie,et al. A high-throughput screening-compatible homogeneous time-resolved fluorescence assay measuring the glycohydrolase activity of human poly(ADP-ribose) glycohydrolase. , 2016, Analytical biochemistry.
[4] Ian O. Ellis,et al. Camptothecin targets WRN protein: mechanism and relevance in clinical breast cancer , 2016, Oncotarget.
[5] E. Friedman,et al. The risk for developing cancer in Israeli ATM, BLM, and FANCC heterozygous mutation carriers. , 2016, Cancer genetics.
[6] G. Ball,et al. Clinicopathological and prognostic significance of RECQL5 helicase expression in breast cancers. , 2016, Carcinogenesis.
[7] B. Waszkowycz,et al. Abstract C39: First-in-class inhibitors of the putatively undruggable DNA repair target Poly(ADP-ribose) glycohydrolase (PARG) , 2015 .
[8] Kenric Leung,et al. The Life History of 21 Breast Cancers , 2015, Cell.
[9] I. Ellis,et al. DNA repair prognostic index modelling reveals an essential role for base excision repair in influencing clinical outcomes in ER negative and triple negative breast cancers , 2015, Oncotarget.
[10] A. Chen,et al. A phase I study of veliparib (ABT-888) in combination with weekly carboplatin and paclitaxel in advanced solid malignancies and enriched for triple-negative breast cancer (TNBC). , 2015 .
[11] A. Ryan,et al. ATM and ATR as therapeutic targets in cancer. , 2015, Pharmacology & therapeutics.
[12] I. Ellis,et al. DNA damage response markers are differentially expressed in BRCA-mutated breast cancers , 2015, Breast Cancer Research and Treatment.
[13] G. Ball,et al. Transcriptomic and Protein Expression Analysis Reveals Clinicopathological Significance of Bloom Syndrome Helicase (BLM) in Breast Cancer , 2015, Molecular Cancer Therapeutics.
[14] Ayala Hubert,et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] G. Ball,et al. Targeting BRCA1‐BER deficient breast cancer by ATM or DNA‐PKcs blockade either alone or in combination with cisplatin for personalized therapy , 2015, Molecular oncology.
[16] A. Psyrri,et al. Beyond BRCA: new hereditary breast cancer susceptibility genes. , 2015, Cancer treatment reviews.
[17] Wei-jia Gao,et al. The association between the APE1 Asp148Glu polymorphism and prostate cancer susceptibility: a meta-analysis based on case–control studies , 2015, Molecular Genetics and Genomics.
[18] I. Ellis,et al. Is There a Role for Base Excision Repair in Estrogen/Estrogen Receptor-Driven Breast Cancers? , 2014, Antioxidants & redox signaling.
[19] Bo Gao,et al. Association between RECQL5 genetic polymorphisms and susceptibility to breast cancer , 2014, Tumor Biology.
[20] B. Waszkowycz,et al. Abstract 2745: Pharmacological characterisation of cell active inhibitors of Poly(ADP-ribose) glycohydrolase (PARG) , 2014 .
[21] G. Ball,et al. Genomic and protein expression analysis reveals flap endonuclease 1 (FEN1) as a key biomarker in breast and ovarian cancer , 2014, Molecular oncology.
[22] Zihui Xu,et al. Curcumin inhibits proliferation of breast cancer cells through Nrf2-mediated down-regulation of Fen1 expression , 2014, The Journal of Steroid Biochemistry and Molecular Biology.
[23] Weiying Zhou,et al. TGFβ Induces “BRCAness” and Sensitivity to PARP Inhibition in Breast Cancer by Regulating DNA-Repair Genes , 2014, Molecular Cancer Research.
[24] E. Winer,et al. Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[25] Jenny C. Chang,et al. Histone deacetylase inhibitor treatment induces ‘BRCAness’ and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells , 2014, Oncotarget.
[26] J. Hoeijmakers,et al. Understanding nucleotide excision repair and its roles in cancer and ageing , 2014, Nature Reviews Molecular Cell Biology.
[27] James H. Doroshow,et al. Rationale for Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Combination Therapy with Camptothecins or Temozolomide Based on PARP Trapping versus Catalytic Inhibition , 2014, The Journal of Pharmacology and Experimental Therapeutics.
[28] D. Cortez,et al. ATR pathway inhibition is synthetically lethal in cancer cells with ERCC1 deficiency. , 2014, Cancer research.
[29] C. Caldon,et al. Estrogen Signaling and the DNA Damage Response in Hormone Dependent Breast Cancers , 2014, Front. Oncol..
[30] T. Dörk,et al. Double heterozygotes among breast cancer patients analyzed for BRCA1, CHEK2, ATM, NBN/NBS1, and BLM germ-line mutations , 2014, Breast Cancer Research and Treatment.
[31] Jian-Min Yuan,et al. Serum estrogen receptor bioactivity and breast cancer risk among postmenopausal women. , 2014, Endocrine-related cancer.
[32] B. Leyland-Jones,et al. Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness. , 2014, Neoplasia.
[33] P. Jarzemski,et al. A common nonsense mutation of the BLM gene and prostate cancer risk and survival. , 2013, Gene.
[34] J. Reis-Filho,et al. Tackling the Diversity of Triple-Negative Breast Cancer , 2013, Clinical Cancer Research.
[35] Rodney Rothstein,et al. Repair of strand breaks by homologous recombination. , 2013, Cold Spring Harbor perspectives in biology.
[36] A. Paradiso,et al. BRCAness: a deeper insight into basal-like breast tumors. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[37] Chris Sander,et al. Emerging landscape of oncogenic signatures across human cancers , 2013, Nature Genetics.
[38] David T. W. Jones,et al. Signatures of mutational processes in human cancer , 2013, Nature.
[39] Xiaojing Guo,et al. Estrogen Receptor α Regulates ATM Expression through miRNAs in Breast Cancer , 2013, Clinical Cancer Research.
[40] Samuel H. Wilson,et al. Interaction between DNA Polymerase β and BRCA1 , 2013, PloS one.
[41] A. Chen,et al. Efficacy of the combination of ABT-888 (veliparib) and carboplatin in patients with BRCA-associated breast cancer. , 2013 .
[42] S. Rodenhuis,et al. Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers , 2013, British Journal of Cancer.
[43] K. Kinzler,et al. Cancer Genome Landscapes , 2013, Science.
[44] Graham Ball,et al. Targeting XRCC1 deficiency in breast cancer for personalized therapy. , 2013, Cancer research.
[45] David M. Wilson,et al. Small Molecule Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1) , 2013 .
[46] P. Hieter,et al. An Evolutionarily Conserved Synthetic Lethal Interaction Network Identifies FEN1 as a Broad-Spectrum Target for Anticancer Therapeutic Development , 2013, PLoS genetics.
[47] R. Brosh,et al. DNA helicases associated with genetic instability, cancer, and aging. , 2013, Advances in experimental medicine and biology.
[48] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumours , 2013 .
[49] I. Ellis,et al. Clinicopathological significance of human apurinic/apyrimidinic endonuclease 1 (APE1) expression in oestrogen-receptor-positive breast cancer , 2013, Breast Cancer Research and Treatment.
[50] N. Curtin,et al. DNA-PK inhibition by NU7441 sensitizes breast cancer cells to ionizing radiation and doxorubicin , 2013, Breast Cancer Research and Treatment.
[51] C. Laughton,et al. Synthetic lethal targeting of DNA double‐strand break repair deficient cells by human apurinic/apyrimidinic endonuclease inhibitors , 2012, International journal of cancer.
[52] P. Pandolfi,et al. Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. , 2012, Cancer discovery.
[53] Lei He,et al. PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. , 2012, Cancer discovery.
[54] G. Tell,et al. Acetylation on critical lysine residues of Apurinic/apyrimidinic endonuclease 1 (APE1) in triple negative breast cancers. , 2012, Biochemical and biophysical research communications.
[55] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumors , 2012, Nature.
[56] A. Sivachenko,et al. Sequence analysis of mutations and translocations across breast cancer subtypes , 2012, Nature.
[57] A. Børresen-Dale,et al. Mutational Processes Molding the Genomes of 21 Breast Cancers , 2012, Cell.
[58] A. Børresen-Dale,et al. The landscape of cancer genes and mutational processes in breast cancer , 2012, Nature.
[59] F. Markowetz,et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.
[60] Irmtraud M. Meyer,et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers , 2012, Nature.
[61] H. Bryant,et al. Inhibition of poly(ADP-ribose) glycohydrolase (PARG) specifically kills BRCA2-deficient tumor cells , 2012, Cell cycle.
[62] C. Eng,et al. Lifetime Cancer Risks in Individuals with Germline PTEN Mutations , 2012, Clinical Cancer Research.
[63] N. Neamati,et al. Small-molecule inhibitors of APE1 DNA repair function: an overview. , 2012, Current molecular pharmacology.
[64] H. Mackay,et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. , 2011, The Lancet. Oncology.
[65] Y. Pommier,et al. Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. , 2011, Cancer research.
[66] E. Cavalieri,et al. Unbalanced metabolism of endogenous estrogens in the etiology and prevention of human cancer , 2011, The Journal of Steroid Biochemistry and Molecular Biology.
[67] Kwok-Kin Wong,et al. COMPROMISED CDK1 ACTIVITY SENSITIZES BRCA-PROFICIENT CANCERS TO PARP INHIBITION , 2011, Nature Medicine.
[68] Stephen C. West,et al. DNA interstrand crosslink repair and cancer , 2011, Nature Reviews Cancer.
[69] J. Tainer,et al. Human Flap Endonuclease Structures, DNA Double-Base Flipping, and a Unified Understanding of the FEN1 Superfamily , 2011, Cell.
[70] Y. Drew,et al. Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2. , 2011, Journal of the National Cancer Institute.
[71] Scott H. Kaufmann,et al. Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells , 2011, Proceedings of the National Academy of Sciences.
[72] L. Finger,et al. Functional regulation of FEN1 nuclease and its link to cancer , 2010, Nucleic acids research.
[73] K. Gelmon,et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2011 .
[74] John A Tainer,et al. A structural model for regulation of NHEJ by DNA-PKcs autophosphorylation. , 2010, DNA repair.
[75] S. Elledge,et al. The DNA damage response: making it safe to play with knives. , 2010, Molecular cell.
[76] A. Simeonov,et al. Small molecule inhibitors of DNA repair nuclease activities of APE1 , 2010, Cellular and Molecular Life Sciences.
[77] Mark Robson,et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2010, The Lancet.
[78] A. Tutt,et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial , 2010, The Lancet.
[79] S. Burma,et al. PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors. , 2010, Cancer research.
[80] M. Lieber,et al. The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway. , 2010, Annual review of biochemistry.
[81] Jan Lubinski,et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[82] J. Dahm-Daphi,et al. The alternative end-joining pathway for repair of DNA double-strand breaks requires PARP1 but is not dependent upon microhomologies , 2010, Nucleic acids research.
[83] E. Rosen,et al. Transcriptional Regulation of the Base Excision Repair Pathway by BRCA1* , 2010, The Journal of Biological Chemistry.
[84] A. Børresen-Dale,et al. COMPLEX LANDSCAPES OF SOMATIC REARRANGEMENT IN HUMAN BREAST CANCER GENOMES , 2009, Nature.
[85] A. Ashworth,et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.
[86] P. Ellis,et al. ABT-888 Confers Broad In vivo Activity in Combination with Temozolomide in Diverse Tumors , 2009, Clinical Cancer Research.
[87] G. Hannon,et al. The estrogen receptor-α-induced microRNA signature regulates itself and its transcriptional response , 2009, Proceedings of the National Academy of Sciences.
[88] T. Helleday,et al. PARP is activated at stalled forks to mediate Mre11‐dependent replication restart and recombination , 2009, The EMBO journal.
[89] Jung-Sik Kim,et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors , 2009, EMBO molecular medicine.
[90] J. Parvin,et al. Cdk1 participates in BRCA1-dependent S phase checkpoint control in response to DNA damage. , 2009, Molecular cell.
[91] E. Levin,et al. Estrogen inhibits ATR signaling to cell cycle checkpoints and DNA repair. , 2009, Molecular biology of the cell.
[92] T. Pandita,et al. Cell cycle checkpoint defects contribute to genomic instability in PTEN deficient cells independent of DNA DSB repair , 2009, Cell cycle.
[93] E. Alli,et al. Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase. , 2009, Cancer research.
[94] Hongbing Shen,et al. A polymorphism in Werner syndrome gene is associated with breast cancer susceptibility in Chinese women , 2009, Breast Cancer Research and Treatment.
[95] Giu-Cheng Hsu,et al. Genetic variants of BLM interact with RAD51 to increase breast cancer susceptibility. , 2009, Carcinogenesis.
[96] A. Ashworth,et al. A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity. , 2008, DNA repair.
[97] I. Ellis,et al. Expression of BRCA1 protein in breast cancer and its prognostic significance. , 2008, Human pathology.
[98] Thomas Helleday,et al. DNA repair pathways as targets for cancer therapy , 2008, Nature Reviews Cancer.
[99] Giovanni Parmigiani,et al. Meta-analysis of BRCA1 and BRCA2 penetrance. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[100] Hiroshi Suzuki,et al. Decreased PARP-1 levels accelerate embryonic lethality but attenuate neuronal apoptosis in DNA polymerase beta-deficient mice. , 2007, Biochemical and biophysical research communications.
[101] P. Pandolfi,et al. Essential Role for Nuclear PTEN in Maintaining Chromosomal Integrity , 2007, Cell.
[102] Thomas Helleday,et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2007, Nature.
[103] Alan Ashworth,et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. , 2006, Cancer research.
[104] T. Helleday,et al. Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair , 2006, Nucleic acids research.
[105] T. Walsh,et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. , 2006, JAMA.
[106] Dieter Niederacher,et al. Interaction of Werner and Bloom syndrome genes with p53 in familial breast cancer. , 2005, Carcinogenesis.
[107] M. Sternberg,et al. Isolation of a small molecule inhibitor of DNA base excision repair , 2005, Nucleic acids research.
[108] T. Helleday,et al. Spontaneous Homologous Recombination Is Induced by Collapsed Replication Forks That Are Caused by Endogenous DNA Single-Strand Breaks , 2005, Molecular and Cellular Biology.
[109] Thomas Helleday,et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2005, Nature.
[110] Alan Ashworth,et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.
[111] Jiri Bartek,et al. The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair , 2005, Nature Cell Biology.
[112] Zhao-Qi Wang,et al. Human Fanconi anemia monoubiquitination pathway promotes homologous DNA repair. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[113] A. Ashworth,et al. Hallmarks of 'BRCAness' in sporadic cancers , 2004, Nature Reviews Cancer.
[114] A. Ashworth,et al. DSS1 is required for RAD51 focus formation and genomic stability in mammalian cells , 2004, EMBO reports.
[115] Huichen Wang,et al. ATR Affecting Cell Radiosensitivity Is Dependent on Homologous Recombination Repair but Independent of Nonhomologous End Joining , 2004, Cancer Research.
[116] K. J. Patel,et al. The Fanconi anaemia gene FANCC promotes homologous recombination and error-prone DNA repair. , 2004, Molecular cell.
[117] Zhao-Qi Wang,et al. Ablation of PARP-1 does not interfere with the repair of DNA double-strand breaks, but compromises the reactivation of stalled replication forks , 2004, Oncogene.
[118] Benjamin J. Raphael,et al. Mutation in Rpa1 results in defective DNA double-strand break repair, chromosomal instability, and cancer in mice , 2004 .
[119] Zhihui Feng,et al. Chk2 Phosphorylation of BRCA1 Regulates DNA Double-Strand Break Repair , 2004, Molecular and Cellular Biology.
[120] Hiroshi Suzuki,et al. Function of poly(ADP-ribose) polymerase in response to DNA damage: Gene-disruption study in mice , 1999, Molecular and Cellular Biochemistry.
[121] T. Helleday,et al. Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination. , 2003, Nucleic acids research.
[122] T. Key,et al. Oestrogen exposure and breast cancer risk , 2003, Breast Cancer Research.
[123] S. Powell,et al. Chk 2 Phosphorylation of BRCA 1 Regulates DNA Double-Strand Break Repair , 2003 .
[124] Shunichi Takeda,et al. Nbs1 is essential for DNA repair by homologous recombination in higher vertebrate cells , 2002, Nature.
[125] J. Ford,et al. BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair , 2002, Nature Genetics.
[126] T. Key,et al. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. , 2002, Journal of the National Cancer Institute.
[127] M. Kelley,et al. Elevated and altered expression of the multifunctional DNA base excision repair and redox enzyme Ape1/ref-1 in prostate cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[128] K. Fidelis,et al. Functional characterization of Ape1 variants identified in the human population. , 2000, Nucleic acids research.
[129] M. Kelley,et al. Alterations in the expression of the DNA repair/redox enzyme APE/ref-1 in epithelial ovarian cancers. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[130] A. Shinohara,et al. The controlling role of ATM in homologous recombinational repair of DNA damage , 2000, The EMBO journal.
[131] C. Anderson,et al. DNA-PK, the DNA-activated protein kinase, is differentially expressed in normal and malignant human tissues , 1999, Oncogene.
[132] P. Chambon,et al. Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[133] A. Harris,et al. Human apurinic endonuclease 1 expression in a colorectal adenoma-carcinoma sequence. , 1997, Cancer research.
[134] J. Hoeijmakers,et al. Disruption of Mouse RAD54 Reduces Ionizing Radiation Resistance and Homologous Recombination , 1997, Cell.
[135] E. Wagner,et al. Mice lacking ADPRT and poly(ADP-ribosyl)ation develop normally but are susceptible to skin disease. , 1995, Genes & development.
[136] M. Swift,et al. Breast and other cancers in families with ataxia-telangiectasia. , 1987, The New England journal of medicine.